Lipocine Inc.
Lipocine Inc. (LPCN): 1 pipeline candidate · ~32 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
31.8 months
D/E 0.11 · 0% dilution
Lead: Phase 3
1 candidate
N/A
4 buys · 0 sells (180d)
A transparent, data-derived signal for Lipocine Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$19.3M
Cash
$5.0M
Quarterly Burn
$2.3M
Runway
31.8 mo
Revenue
$119K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| lpcn 1154a | Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
39
Total value held
$12.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 401,336 | $3.2M |
| stempoint capital lp | 320,840 | $2.6M |
| boothbay fund management, llc | 140,487 | $1.1M |
| blackrock, inc. | 89,272 | $713K |
| geode capital management, llc | 63,135 | $505K |
| exome asset management llc | 60,861 | $486K |
| diadema partners lp | 50,000 | $400K |
| j. goldman & co lp | 42,170 | $337K |
| renaissance technologies llc | 38,497 | $308K |
| two sigma investments, lp | 33,750 | $270K |
Showing top 10 of 39 institutional holders of Lipocine Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Lipocine Inc.'s pipeline?
Lipocine Inc. (LPCN) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Lipocine Inc.'s lead drug candidate?
Lipocine Inc.'s most advanced tracked candidate is lpcn 1154a (Phase 3) for Depression, Postpartum.
What is Lipocine Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Lipocine Inc. has approximately 31.8 months of cash runway.
What is Lipocine Inc.'s market capitalization?
Lipocine Inc.'s market capitalization is approximately $19.3M.
Who is the CEO of Lipocine Inc.?
Dr. Mahesh V. Patel Ph.D. is the chief executive officer of Lipocine Inc. (LPCN).
Get the full picture on Lipocine Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.